Resource Type

Journal Article 844

Conference Videos 9

Year

2024 32

2023 62

2022 80

2021 78

2020 54

2019 66

2018 55

2017 60

2016 34

2015 38

2014 36

2013 45

2012 35

2011 28

2010 18

2009 39

2008 20

2007 24

2006 6

2005 8

open ︾

Keywords

dynamic response 14

fuel cell 13

immunotherapy 10

response surface methodology 10

COVID-19 7

Response surface methodology 7

hepatocellular carcinoma 7

seismic response 6

solar cell 6

demand response 5

hematopoietic stem cell transplantation 5

hydrogen energy 5

stem cell 5

SARS-CoV-2 4

cell proliferation 4

control 4

lung cancer 4

microbial fuel cell 4

solid oxide fuel cell 4

open ︾

Search scope:

排序： Display mode:

Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection

Yun Tan, Feng Liu, Xiaoguang Xu, Yun Ling, Weijin Huang, Mingquan Guo, Ziyu Fu, Dongguo Liang, Miao Xu, Hongzhou Lu, Saijuan Chen

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 746-751 doi: 10.1007/s11684-020-0822-5

Abstract: showed significant neutralizing activities in a pseudovirus assay, with no difference in blocking the cell-entryFurthermore, in 10 blood samples from cases at 6−7 months post-infection used for memory T-cell tests

Keywords： SARS-CoV-2     neutralizing antibodies     T-cell response    

HTML PDF Collect

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Frontiers of Medicine 2021, Volume 15, Issue 6,   Pages 783-804 doi: 10.1007/s11684-021-0904-z

Abstract: Chimeric antigen receptor T-cell (CAR T) immunotherapy opens a new path for targeted therapy of hematologicalIn this review, through a representative case study, we summarize the current experience of CAR T-cell, the causative mechanisms of therapy resistance, and new strategies to improve the efficacy of CAR T-cell

Keywords： CAR T cells     hematological malignancies     review    

HTML PDF Collect

Clinical characteristics and prognostic factors of patients with mature T-cell lymphoid malignancies:

Wen Xue,Yan Sheng,Xiangqin Weng,Yongmei Zhu,Yan Zhao,Pengpeng Xu,Xiaochun Fei,Xiaoyan Chen,Li Wang,Weili Zhao

Frontiers of Medicine 2015, Volume 9, Issue 4,   Pages 468-477 doi: 10.1007/s11684-015-0419-6

Abstract:

Mature T-cell lymphoid malignancies comprise a group of heterogeneous diseases that vary in clinicopathologicalBone marrow (BM) infiltration is more commonly present in mature T-cell lymphoid malignancies comparedthis study, clinical characteristics and prognostic factors were analyzed in 225 patients with mature T-cellThese included 29 cases of T-cell lymphoproliferative disorders (T-LPD, all with BM infiltration) andconclusion, clinical characteristics may be useful in more effectively stratifying patients with mature T-cell

Keywords： mature T-cell lymphoid malignancies     clonal T-cell population     bone marrow infiltration     prognostic factors    

HTML PDF Collect

Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 442-458 doi: 10.1007/s11684-021-0877-y

Abstract: T-cell acute lymphoblastic leukemia (T-ALL) is one of the most dangerous hematological malignancies,More than 60% of T-ALL patients carry NOTCH1 gene mutations, leading to abnormal expression ofWe found that chidamide, an HDAC inhibitor, exerts an antitumor effect on T-ALL cell lines and primaryOur results highlight the effectiveness and safety of chidamide in the treatment of T-ALL patients, including

Keywords： T-cell acute lymphoblastic leukemia     HDAC inhibitor     chidamide     NOTCH1     MYC     ubiquitination    

HTML PDF Collect

Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia

Meilin Ma, Xiang Wang, Jingyan Tang, Huiliang Xue, Jing Chen, Ci Pan, Hua Jiang, Shuhong Shen

Frontiers of Medicine 2012, Volume 6, Issue 4,   Pages 416-420 doi: 10.1007/s11684-012-0224-4

Abstract:

Acute lymphoblastic leukemia includes T-cell acute lymphoblastic leukemia (T-ALL) and B-cell acutephenotype that resembles early T-cell precursor, which confers a much poorer prognosis than any otherform of T-ALL.This novel subtype of T-ALL was called early T-cell precursor acute lymphoblastic leukemia (ETP-ALL).Our findings demonstrate that early T-cell precursor leukemia is a very high-risk subtype of acute lymphoblastic

Keywords： acute lymphoblastic leukemia     early T precursor     prognosis    

HTML PDF Collect

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 711-725 doi: 10.1007/s11684-020-0808-3

Abstract: Chimeric antigen receptor T (CAR-T) cells were introduced as a treatment for these patients.achieved complete remission after receiving the CD19 CAR-T cell therapy.cell therapy.Therefore, optimizing the structure of CAR, creating new drugs, and combining CAR-T cell therapy withthe toxicity in patients with lymphoma after the CAR-T cell therapy.

Keywords： chimeric antigen receptor T (CAR-T) cell     lymphoma     cytokine release syndrome (CRS)     immune effector cell-associated    

HTML PDF Collect

EBV-associated lymphoproliferative disease post-CAR-T cell therapy

Frontiers of Medicine 2024, Volume 18, Issue 2,   Pages 394-398 doi: 10.1007/s11684-023-1032-8

Abstract: common complications that occur after solid organ transplantation or allogeneic hematopoietic stem-cellHowever, their occurrence and treatment post-chimeric antigen receptor-modified T (CAR-T) cell therapyAfter receiving CAR-T cell therapy in tandem with autologous HSCT, the patients achieved complete remissionHowever, with a median time of 38.5 months after CAR-T cell therapy, B-cell-derived EBV-LPDs were diagnosedCollectively, our report suggests that EBV-LPDs may represent a long-term adverse event after CAR-T cell

Keywords： EBV-associated lymphoproliferative disease     chimeric antigen receptor T-cell     autologous stem cell transplantation    

HTML PDF Collect

Change and significance of T-cell subsets and TNF-α in patients with advanced malignant obstructive jaundice

ZHU Lidong, CHEN Xiaoping

Frontiers of Medicine 2007, Volume 1, Issue 4,   Pages 364-368 doi: 10.1007/s11684-007-0070-y

Abstract: The aim of this article was to study the influence of immunity function of advanced malignant obstructive jaundice (MOJ) treated by percutaneous transhepatic biliary external and internal drainage. Ninety-six cases of MOJ were divided into two groups according to the different ways of biliary drainage. Fifty-two external drainage tubes were placed in 41 cases of percutaneous transhepatic biliary external drainage group and 66 metal stents were placed in 55 cases of percutaneous transhepatic biliary internal drainage group. Liver function, serum TNF- and cellular function were examined one day before operation and one week after operation and liver function was re-examined two weeks after operation, in order to observe the change and analyze the asso ciation among them and compare with the control group. All patients conditions were improved after operation. In the percutaneous transhepatic biliary external and internal drainage groups, the total level of bilirubin decreased from (343.54±105.56) μ mol/L and (321.19±110.50) μ mol/L to (290.56±103.46) μ mol/L and (283.72±104.95) μ mol/L after operation respectively, which were significantly lower than pre-operation (<0.05), but there was no significant difference between the two groups (>0.05). Serum alanine aminotransferase (ALT) of all patients one week after operation was significantly lower than that before operation. TNF- in percutaneous transhepatic biliary external and internal groups decreased from (108.58±19.95) pg/mL, (109.98±16.24) pg/mL of pre-operation to (104.32±19.59) pg/mL, (83.92±13.43) pg/mL of post-operation respectively, there was notable improvement (<0.01) in internal drainage group after operation. Patients serum CD4, CD3 and CD4/CD8 were notably increased, but CD8 was notably decreased (<0.05). There was no difference in external drainage group (>0.05). There was a significant difference between the two groups. Serum TNF- and ALT had positive correlation. Percutaneous transhepatic biliary internal or external drainage was an effective and important method to treat MOJ. Patients immune function was weak when they suffered MOJ, but body s cellular immune function can be notably improved after internal biliary drainage.
HTML PDF Collect

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 811-815 doi: 10.1007/s11684-020-0740-6

Abstract: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for r/r non-HodgkinHowever, long-term safety and tolerability associated with CAR T-cell therapy are not defined well, especiallypatient with r/r MCL with 48-month duration of follow-up who achieved long-term remission after CAR T-cellCAR T-cell-related toxicities were also mild and tolerated well even in this elderly patient.This report suggested that CAR T-cell therapy is a promising treatment modality for patients with MCL

Keywords： anti-CD19 chimeric antigen receptor T cells     mantle cell lymphoma     relapsed or refractory     long-term follow-up    

HTML PDF Collect

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 689-700 doi: 10.1007/s11684-020-0759-8

Abstract: and other preclinical methods have identified several high-risk subtypes, such as hypodiplod, early T-cellprecursor, immature T-cell, -rearranged, Ph-positive and -positive ALL, that may respond to BCL-2targetable genetic lesions, current approaches that offer hope include blinatumomab, inotuzumab and CAR-Tcell therapy for B-ALL, and daratumumab and nelarabine for T-ALL.

Keywords： lymphoblastic leukemia     molecular therapeutics     targeted therapy     tyrosine kinase inhibitors     immunotherapy     CAR T-cell    

HTML PDF Collect

Deubiquitinases as pivotal regulators of T cell functions

Xiao-Dong Yang, Shao-Cong Sun

Frontiers of Medicine 2018, Volume 12, Issue 4,   Pages 451-462 doi: 10.1007/s11684-018-0651-y

Abstract:

T cells efficiently respond to foreign antigens to mediate immune responses against infections butDefect in T cell activation is associated with severe immune deficiencies, whereas aberrant T cell activationAn emerging mechanism that regulates T cell activation and tolerance is ubiquitination, a reversibleIt is now well recognized that DUBs are crucial regulators of T cell responses and serve as potentialThis review will discuss the recent progresses regarding the functions of DUBs in T cells.

Keywords： deubiquitinase     ubiquitination     T cell activation     T cell differentiation     T cell tolerance    

HTML PDF Collect

Regulation of T cell immunity by cellular metabolism

Zhilin Hu, Qiang Zou, Bing Su

Frontiers of Medicine 2018, Volume 12, Issue 4,   Pages 463-472 doi: 10.1007/s11684-018-0668-2

Abstract:

T cells are an important adaptive immune response arm that mediates cell-mediated immunity.T cell metabolism plays a central role in T cell activation, proliferation, differentiation, and effectorSpecific metabolic programs are tightly controlled to mediate T cell immune responses, and alterationsin T cell metabolism may result in many immunological disorders.in T cell metabolic programming during T cell homeostasis, differentiation, and function.

Keywords： T cell immunity     metabolic pathways     nutrient uptake     metabolic checkpoints    

HTML PDF Collect

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 701-710 doi: 10.1007/s11684-020-0763-z

Abstract: Abstract Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cellAllogeneic hematopoietic stem cell transplantation could be an effective therapy because of the graft-versus-leukemiaAlthough the identification of an ideal target antigen for AML is challenging, CAR T therapy remainsIn this review, we focus on the most recent and promising advances in CAR T therapies for AML.

Keywords： acute myeloid leukemia     CAR T     immunotherapy    

HTML PDF Collect

High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells

Synat Kang, Yanyan Li, Yifeng Bao, Yi Li

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 69-82 doi: 10.1007/s11684-018-0677-1

Abstract:

Cytokine-activated T cells (CATs) can be easily expanded and are widely applied to cancer immunotherapyThe low-efficacy problem can be resolved using T cell antigen receptor-engineered CAT (TCR-CAT).TCR-CATs delivered significantly better activation and cytotoxicity than the equivalent TCR-engineered Tinterferon-g and granzyme B production and in vitro cancer cellTCR-CAT may be a very good alternative to the expensive TCR-T, which is considered an effective personalized

Keywords： cytokine-activated T cells     high-affinity T cell receptor     cancer immunotherapy     TCR-CAT    

HTML PDF Collect

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cellA single-center phase I dose-escalation study was conducted to evaluate the safety and efficacy of Tbearing 4-1BB costimulatory molecule, for the treatment of patients with refractory diffuse large B-cellTen heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell (C-CAR011) treatmentThe overall response rate was 20% and 50% at 4 and 12 weeks after the infusion of C-CAR011, respectively

Keywords： CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting    

HTML PDF Collect

Title Author Date Type Operation

Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection

Yun Tan, Feng Liu, Xiaoguang Xu, Yun Ling, Weijin Huang, Mingquan Guo, Ziyu Fu, Dongguo Liang, Miao Xu, Hongzhou Lu, Saijuan Chen

Journal Article

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Journal Article

Clinical characteristics and prognostic factors of patients with mature T-cell lymphoid malignancies:

Wen Xue,Yan Sheng,Xiangqin Weng,Yongmei Zhu,Yan Zhao,Pengpeng Xu,Xiaochun Fei,Xiaoyan Chen,Li Wang,Weili Zhao

Journal Article

Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia

Journal Article

Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia

Meilin Ma, Xiang Wang, Jingyan Tang, Huiliang Xue, Jing Chen, Ci Pan, Hua Jiang, Shuhong Shen

Journal Article

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Journal Article

EBV-associated lymphoproliferative disease post-CAR-T cell therapy

Journal Article

Change and significance of T-cell subsets and TNF-α in patients with advanced malignant obstructive jaundice

ZHU Lidong, CHEN Xiaoping

Journal Article

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Journal Article

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Journal Article

Deubiquitinases as pivotal regulators of T cell functions

Xiao-Dong Yang, Shao-Cong Sun

Journal Article

Regulation of T cell immunity by cellular metabolism

Zhilin Hu, Qiang Zou, Bing Su

Journal Article

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Journal Article

High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells

Synat Kang, Yanyan Li, Yifeng Bao, Yi Li

Journal Article

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Journal Article